Holen Sie sich die Stockscreener-App
0.4178
5.49%
-0.0243
Schlusskurs vom Vortag:
$0.442
Offen:
$0.45
24-Stunden-Volumen:
142.41K
Relative Volume:
0.24
Marktkapitalisierung:
$8.52M
Einnahmen:
Nettoeinkommen (Verlust:
$-30.33M
KGV:
-0.0149
EPS:
-28.0369
Netto-Cashflow:
$-24.28M
1W Leistung:
-12.35%
1M Leistung:
-41.57%
6M Leistung:
-84.06%
1J Leistung:
-96.47%
1-Tages-Spanne:
$0.41
$0.4531
1-Wochen-Bereich:
$0.4107
$0.49
52-Wochen-Spanne:
$0.1614
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.4178 | 8.52M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
508.13 | 128.79B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
211.62 | 84.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
763.14 | 78.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
815.75 | 51.30B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.52 | 41.26B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit - Yahoo! Finance Canada
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit - GlobeNewswire
Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting (NASDAQ:MBRX) - www.hastingsstargazette.com
Form 8-K Moleculin Biotech, Inc. For: Oct 05 - StreetInsider
Moleculin Biotech stock reaches 89-patient MIRACLE milestone2d4f8a6b-9c3e-4f1a-b7d2-5e8c0a6f3b91 - AD HOC NEWS
Price to earnings forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Certain Pre-Funded Warrants of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 3-OCT-2026. - marketscreener.com
Moleculin Biotech CS (MBRX-Q) Stock Price and News - The Globe and Mail
Moleculin completes enrollment in Annamycin AML trial Part A - Investing.com
Form 8K Moleculin Biotech Inc For: 29 September By Investing.com - Investing.com UK
Moleculin completes enrollment in Annamycin AML trial Part A By Investing.com - Investing.com Canada
Moleculin Biotech completes Part A enrollment in MIRACLE; 89 patients, Q1 2027 readout on track - TradingView
Moleculin Biotech Completes Enrollment in Part A of Phase - GlobeNewswire
A leukemia trial finished enrolling 89 people. Full results are expected in early 2027. - Stock Titan
Moleculin Biotech Reports Peer-Reviewed Cardiac Safety Analysis of Annamycin - Kalkine Media
Moleculin reports cardiac safety data for Annamycin in study - Investing.com
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine - GlobeNewswire Inc.
A review found no signs of heart damage in 90 patients given a cancer drug - Stock Titan
Moleculin Announces Publication of Peer-Reviewed Cardiac - globenewswire.com
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com Nigeria
Moleculin presents preclinical pancreatic cancer data at AACR - Investing.com
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com UK
A cancer drug may help immune cells attack pancreatic tumors, early tests suggest. - Stock Titan
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Moleculin Biotech (NASDAQ: MBRX) Obtains Mexican Patent No. 436849 and Issues 888,400 Shares via ATM Offering - Kalkine Media
Moleculin Biotech Announces Mexican Patent Approval and ATM Share Offering Completion - Kalkine Media
Moleculin Biotech (MBRX) Strengthens IP with Mexican Patent Amid Challenging Valuation - GuruFocus
Form 8K Moleculin Biotech Inc For: 23 September By Investing.com - Investing.com Canada
Moleculin receives Mexican patent for Annamycin formulation - Investing.com
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 - globenewswire.com
A drug formulation designed to reach lung tumors has Mexican patent protection through 2040. - Stock Titan
Moleculin Biotech stock falls 32.71 percent on September 21 - AD HOC NEWS
Form 8K Moleculin Biotech Inc For: 18 September By Investing.com - Investing.com Nigeria
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation - Investing.com
Moleculin Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Moleculin Biotech risks Nasdaq delisting after shares stay below $1 bid threshold - Bitget
Moleculin to Showcase New Annamycin Data at AACR Conference - GlobeNewswire
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Australia
Moleculin Biotech at H.C. Wainwright conference: aml hope builds - Investing.com
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Canada
MBRX: Annamycin's Phase III AML trial shows triple the remission rate of control with zero cardiotoxicity - TradingView
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
A biotech’s clinical update goes online before New York investor meetings - stocktitan.net
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance
Moleculin Biotech (MBRX) Holds Above $0.77 as Biotech Sector Watches Key Resistance at $0.81Trend Following Picks - siam.in
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - ACCESS Newswire
Moleculin Biotech Updates Investors with New Presentation - TipRanks
Moleculin (NASDAQ: MBRX) posts investor presentation online - stocktitan.net
MOLECULIN BIOTECH, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $3 FROM $22 - webull.com
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):